Welcome to our dedicated page for TRXD news (Ticker: TRXD), a resource for investors and traders seeking the latest updates and insights on TRXD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TRXD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TRXD's position in the market.
TRxADE HEALTH (NASDAQ:MEDS) announced its participation at the LD Micro Movers Virtual Event on December 1, 2021. CEO Suren Ajjarapu is set to deliver a 30-minute presentation at 5:00 p.m. Eastern Time. This event highlights notable small-cap companies and offers insights into TRxADE's focus on digitalizing the retail pharmacy experience by enhancing drug procurement and patient engagement. Interested parties can access the live audio webcast through the provided link, with an archived version available later.
TRxADE HEALTH (NASDAQ:MEDS) reported a 34.3% revenue increase for Q3 2021, totaling $2.6 million, up from $1.9 million in Q2 2021. However, revenue declined 58.7% year-over-year, down from $6.3 million due to non-recurring PPE sales in 2020. The gross profit improved to $1.3 million (50.2% margin) versus $1.9 million (30.5% margin) last year. Operating expenses rose to $2.6 million, leading to a net loss of $(1.3) million.
Cash and cash equivalents were $3.6 million at period end.
